Patients’ baseline cannabinoid use is associated with an increased likelihood of requiring high doses of sedation for gastroscopy but not for colonoscopy, according to new research presented at Digestive Disease Week 2022.
Among patients undergoing gastroscopy, those who used cannabinoids at baseline were more likely than nonusers to require high-dose midazolam (=5 mg IV; adjusted odds ratio [aOR], 2.89; 95% CI, 1.19-7.59) and IV diphenhydramine (aOR, 3.04; 95% CI, 1.29-7.30). Baseline